ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,956.06
0.01%
US Tech 100
20,543.60
0.05%
다우존스 지수
43,433.12
-0.43%
Bitcoin
84,938.92
1.03%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Verona Pharma Plc (VRNA) 시세

Verona Pharma Plc

Verona Pharma Plc (VRNA)

NASDAQ
63.52
1.13
(1.81%)
마감 27 2월 6:00AM
15분 지연
65.9994
2.48
(3.90%)
시간외 거래: 9:59AM
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
65.9994
매수가
63.21
매도가
65.79
거래량
1,732,987
62.24 일간 변동폭 65.7056
0.00 52주 범위 0.00
market_cap
5.401B
전일 종가
62.39
개장가
62.24
최근 거래 시간
30
@
65.78
마지막 거래 시간
재정 규모
US$ 111,108,957
VWAP
64.1141
평균 볼륨(3m)
-
발행 주식
81,831,170
배당수익률
-
주가수익률
0.00
주당순이익(EPS)
-
매출
-
순이익
-54.37M

Verona Pharma Plc 정보

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which ... Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.veronapharma.com
본부
London, Gbr
설립됨
-
Verona Pharma Plc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker VRNA. The last closing price for Verona Pharma was US$62.39. Over the last year, Verona Pharma shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Verona Pharma currently has 81,831,170 shares in issue. The market capitalisation of Verona Pharma is US$5.11 billion.

Verona Pharma (VRNA) 옵션 플로우 요약

전체 옵션 플로우 보기

전체 흐름

약세

순 프리미엄

-4M

Calls / Puts

52.00%

매수 / 매도

216.67%

OTM / ITM

245.45%

Sweeps 비율

31.58%

VRNA 최신 뉴스

추가 뉴스

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
05 2월 2025
VRNA (1.81%)

Form 8-K - Current report
Edgar (US Regulatory)
07 1월 2025
VRNA (1.81%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
27 11월 2024
VRNA (1.81%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
26 11월 2024
VRNA (1.81%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
08 11월 2024
VRNA (1.81%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

VRNA - Frequently Asked Questions (FAQ)

What is the current Verona Pharma share price?
The current share price of Verona Pharma is US$ 65.9994
How many Verona Pharma shares are in issue?
Verona Pharma has 81,831,170 shares in issue
What is the market cap of Verona Pharma?
The market capitalisation of Verona Pharma is USD 5.11B
What is the 1 year trading range for Verona Pharma share price?
Verona Pharma has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the reporting currency for Verona Pharma?
Verona Pharma reports financial results in USD
What is the latest annual profit for Verona Pharma?
The latest annual profit of Verona Pharma is USD -54.37M
What is the registered address of Verona Pharma?
The registered address for Verona Pharma is ONE CENTRAL SQUARE, CARDIFF, LONDON, CF10 1FS
What is the Verona Pharma website address?
The website address for Verona Pharma is www.veronapharma.com
Which industry sector does Verona Pharma operate in?
Verona Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
ENVBEnveric Biosciences Inc
US$ 2.27
(92.37%)
134.34M
QVCGBQVC Group Inc
US$ 9.60
(88.98%)
5.44M
PITAHeramba Electric PLC
US$ 0.694
(88.08%)
100.43M
PRCHPorch Group Inc
US$ 6.60
(74.14%)
31.83M
MULNMullen Automotive Inc
US$ 4.035
(70.97%)
92.76M
VEROVenus Concept Inc
US$ 0.326949
(-39.45%)
1.93M
FLYWFlywire Corporation
US$ 11.045
(-37.39%)
24.73M
ILAGIntelligent Living Application Group Inc
US$ 0.5444
(-33.61%)
476.4k
ONVOOrganovo Holdings Inc
US$ 0.8499
(-33.08%)
49.99M
GERNGeron Corp
US$ 1.605
(-32.28%)
92.24M
NVDANVIDIA Corporation
US$ 131.28
(3.67%)
328.62M
TRNRInteractive Strength Inc
US$ 1.2401
(30.58%)
157.21M
LCIDLucid Group Inc
US$ 2.255
(-13.60%)
156.06M
SMCISuper Micro Computer Inc
US$ 51.08
(12.17%)
140.93M
ENVBEnveric Biosciences Inc
US$ 2.27
(92.37%)
134.34M

VRNA Discussion

게시물 보기
powerwalker powerwalker 7 시간 전
Roger, how are you feeling?
👍️0
Roger1 Roger1 12 시간 전
Time of cc signals good news, imo
👍️ 1 🙏 1 🤞 1
powerwalker powerwalker 13 시간 전
Given the quick move to $65.70 and subsequent halving of the gain, it seems MM's still seeking weak hands ... especially with tomorrow's CC before the market opens looming!
👍️0
Hoskuld Hoskuld 2 일 전
Yes the high end is reasonable but the low end seems too low to credit. Zero new patients results in...16,000 patients = $250m per year, divided by 4 gives $62m for current quarter. If they add the bare minimum new patients during CQ (1,000 per week) then that would be average of 22,500 partients = $87m for CQ.
👍️ 1
MegaPirate61 MegaPirate61 2 일 전
Estimated outlook for cq are between 65 and 90 million
👍️0
Hoskuld Hoskuld 3 일 전
Roger, the average for Q4 was just over 1,000 patients per week with momentum building through the end of the year despite holidays. My estimate is, IMO, extremely conservative: no additional growth in new patients per week. This seems unlikely though so I expect those estimates of mine are low.
👍️ 1
Roger1 Roger1 4 일 전
That would be awesome
👍️0
Hoskuld Hoskuld 4 일 전
They had 16,000 patients on ohtuveyre as of 31DEC and I bet they announce that they have 25,000 patients as of 14FEB or 27,000 as of 24FEB.
👍️ 1
Roger1 Roger1 4 일 전
Thanks. Looking forward to seeing quarterlies next week. Anyone speculate on uptake for January?
👍️0
Hoskuld Hoskuld 4 일 전
Roger, buyout would be based on strength of market acceptance and uptake. BP should have already purchased for $100 per share, now the price will be $120 and will grow to $150-$200 as the next year plays out. A buyout could happen at any time - should happen at any time - but who knows?
👍️ 1
Roger1 Roger1 5 일 전
How high does this go before getting taken out?
👍️0
powerwalker powerwalker 1 주 전
I am interested in Verona's comments on filing an MAA with the EMA. Hopefully, they have or will be doing so soon.
👍️0
powerwalker powerwalker 2 주 전
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

https://www.veronapharma.com/news/verona-pharma-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-corporate-update/
👍️0
powerwalker powerwalker 2 주 전
Does anyone have any thoughts as to today's gain?
👍️0
Roger1 Roger1 3 주 전
I can tell you that I've been off steroids for 3 weeks.
👍️ 4 💥 1
powerwalker powerwalker 3 주 전
Hello, Roger:

Is there any update on your condition which you would like to share?

Thank you,
powerwalker
👍️0
Monksdream Monksdream 1 월 전
VRNA 1 yr
👍️ 1
MegaPirate61 MegaPirate61 1 월 전
For 2025, Stan Druckenmiller
made his long pick in the Robin Hood contest in Verona Pharma (VRNA). Verona's inhaled treatment for adults with chronic obstructive pulmonary disease (COPD) won FDA approval last June. On Jan. 8, it said fourth-quarter sales totaled $36 million in the multi-billion dollar blockbuster indication.
👍️ 3
powerwalker powerwalker 1 월 전
Is Verona Pharma (VRNA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

https://finance.yahoo.com/news/verona-pharma-vrna-among-billionaire-201156030.html
👍️ 2 😃 1
MegaPirate61 MegaPirate61 1 월 전
According to a msg board post the cfo said that their quarterly expenses were 50 million and sales were now break even and will soon be exceeding that.
👍️ 2
powerwalker powerwalker 1 월 전
While it might not be making a presentation, Verona execs are at the JPM Healthcare Conference, partaking in meetings with future impact.
👍️0
MegaPirate61 MegaPirate61 2 월 전
Posted a typo before the released shares that were already on the shelf total was 2.5 million shares not 12.5 mil
👍️0
Roger1 Roger1 2 월 전
Yes
👍️ 3
Hoskuld Hoskuld 2 월 전
Do you ascribe this improvement to ohtuvayre Roger? Congratulations!
👍️ 1
Roger1 Roger1 2 월 전
Good news. I've been able to cut my Prednisone in half and hopefully eliminate it soon. Have found I can stretch my nebulizer treatments to Q6-7 from Q4. Will be interesting to see how much more improvement I can get b4 allergy season in Mar/April.
👍️ 3
powerwalker powerwalker 2 월 전
Roger, what is going on with you and your ohtuvayre experience?

We would like to hear about it.
👍️ 2
MegaPirate61 MegaPirate61 2 월 전
Well they went and announced unofficial earnings on their own today. Also says they sold 12.5 million shares at an avg of 39.50 of so through Jeffries. Must have something else to announce at jpm?
👍️ 1
powerwalker powerwalker 2 월 전
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

https://finance.yahoo.com/news/verona-pharma-reports-strong-ohtuvayre-110000636.html

Sounds positive and noted the "J-code" that MegaPirate had emphasized. 👍️❤️
👍️ 1
powerwalker powerwalker 2 월 전
Thank you, MegaPirate, for your reply.
👍️ 1
MegaPirate61 MegaPirate61 2 월 전
I'm not Hoskuld but the company said in q n a session last earnings call that they would announce unaudited q4 2024 sales at jpm around Jan 12 to 14 if I remember right. We will all need to be patient here. A launch doesn't really start until the second quarter of having a j code which is just now active. We will have a better indication in a year of the early results.
👍️0
powerwalker powerwalker 2 월 전
Hoskuld, do you think Verona will be invited to JP Morgan Healthcare Conference next week?
👍️ 1
Hoskuld Hoskuld 2 월 전
That is so great Roger! How has ohtuvayre helped you? Easier to breathe? Less phlegm? Would you be willing to share your experience?
👍️ 2
powerwalker powerwalker 2 월 전
Best of luck, Roger … it is time for a Christmas present for you and your elbow Virginians.

Merry Christmas and a prosperous 2025.
powerwalker
👍️0
Roger1 Roger1 2 월 전
I can tell you the drug works for me. Acaria Pharma, specialty pharmacy filling rx's has thrown a wrench in the works by requiring Virginia patients to have additional Rx from the physician greatly increasing the time needed to fill. Ohtovayre patient portal reps are unaware. I've told 2 of them about it and emailed company but have not received any response. That was several weeks ago. I know my pulmonologist has prescribed it for several patients but I believe I may be the first to actually receive it.
,
👍️ 3
powerwalker powerwalker 2 월 전
GIDDY-UP, VERONA, and all you hedge managers and investment bankers hitch yourselves to this rocket! It is ready to take-off!
👍️ 1
powerwalker powerwalker 3 월 전
Let's go you, Investment advisors and hedge fund managers, get your valuation models going full tilt this weekend to calculate how quickly Verona can get to $100 ... and start buying!
👍️0
powerwalker powerwalker 3 월 전
Hopefully, Verona will break the $40 ceiling and stay above it. Its performance deserves it.
👍️ 1
Hoskuld Hoskuld 3 월 전
PW another claim by management is that this is the best pulmonary launch ever (by far.)
👍️ 2
powerwalker powerwalker 3 월 전
Thank you, Hoskuld. I'll listen to one of the two tomorrow.
👍️0
Hoskuld Hoskuld 3 월 전
I thought it was excellent PW: uptake is strong and docs are prescribing earlier in the disease cycle than anticipated which underscores the hunger for a differentiated therapy. Feedback from docs is good. Based on what he said, I expect the company will be cash flow positive by April.
🎯 1 👍️ 2
powerwalker powerwalker 3 월 전
Any word on today's presentation?
👍️0
Roger1 Roger1 3 월 전
Yes. Still waiting. Seems to be quite a process with Acaria pharmacy, Medicare, coinsurance. No idea where the process is at. I do know dr.s office has done all that's been asked. They are just as interested in any improvement as I am. Have a feeling I'm the guinea pig for this practice. <S>. I wonder if pharmacy is overwhelmed or is there some other reason. I'll let you know if I hear anything. Have a great day. 
👍️ 3
powerwalker powerwalker 3 월 전
Good morning, Roger:

Did the doctor's office get things right, so you are now on Ohtuvayre?

If so, let us know how it is helping.
👍️0
powerwalker powerwalker 3 월 전
Upcoming next week:

Verona Pharma Announces December 2024 Investor Conference Participation
Share

LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:

Piper Sandler 36th Annual Healthcare Conference
Date: Tuesday, December 3, 2024
Time: 12:00 p.m. ET / 5:00 p.m. GMT
Location: New York, NY

7th Annual Evercore HealthCONx Conference
Date: Wednesday, December 4, 2024
Time: 3:00 p.m. ET / 8:00 p.m. GMT
Location: Miami, FL

A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

https://www.veronapharma.com/news/verona-pharma-announces-december-2024-investor-conference-participation/
👍️ 1
MegaPirate61 MegaPirate61 3 월 전
Probably a moot point. If it's a 200 billion dollar asset over time the most big pharma will pay is 20b. And they will take it sooner rather than later. Maybe within the next 2 yrs.
👍️0
Hoskuld Hoskuld 3 월 전
Pricing is the US is pretty sweet - ROW not so much. If bicyclical then the motion will be elliptical.
👍️0
powerwalker powerwalker 3 월 전
Does anyone have thoughts on yesterday's presentation? I read the slides and come away with the impression that Verona can serve 50% of the market with the focus on 80% of the HCPs intent to Prescribe Ohtuvayre.

With $1.1 billion in sales for each !% or 86K patients, those are BIG numbers down the road as Mega and Hoskuld shared earlier this week.
👍️ 1
MegaPirate61 MegaPirate61 3 월 전
Just search fintel Duquesne position of 680k shares you can validate this on multiple sites. Use ai in your searches lol
👍️ 1
powerwalker powerwalker 3 월 전
Mega, article is behind a pay-wall for CNBC, so can't see it.

I think he will buy more ... sooner, rather than later.
👍️0
Roger1 Roger1 3 월 전
It is in process. Mixup at doctors office. Verona and Acaria have been very supportive and helpful. Should be straightened out today.
👍️ 1

최근 히스토리

NASDAQ
VRNA
Verona Pharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지